An independent newsroom of one. Every story is cross-referenced across multiple trusted Indian publications, scored, and rewritten without ads, bias, or noise.

News

Politics
Business
Sports
Technology
World
Entertainment

About

How verification works
Saved stories

Legal

Privacy Policy
Terms of Use
Corrections Policy
Contact & Tips

Transparency

No advertising or sponsored content
Every claim links back to its sources
Open-source under the MIT licence
AI cross-verifies before publishing

Built in IndiaDesigned & engineered by Roshhellwett, with the help of Claude & other tools.

Home

Swipe

Saved

Junshi Biosciences Phase 3 Study Meets Primary Endpoints — India Verified

Back to all news

Health
Junshi Biosciences Phase 3 Study Meets Primary Endpoints

Health28 May 2026 at 08:17 amQuick read

Junshi Biosciences Phase 3 Study Meets Primary Endpoints

Credibility score90 / 100

LowModerateHigh

2sources verified

Junshi Biosciences announced its phase 3 study met primary endpoints. The study involved stage Ⅱ-Ⅲ NSCLC patients. The final analysis was completed.

AI Credibility Analysis

The score is 90 because the information is based on a press release from a reputable company, Junshi Biosciences, and is reported by two sources, Financial Post and GlobeNewswire, with specific details about the phase 3 study and its outcomes.

Original Sources

Financialpost
Globenewswire

How this story was built

Cross-Referenced

2 Sources

Unbiased AI

⚡

Auto-Published

Junshi Biosciences Phase 3 Study Meets Primary Endpoints

How this story was built

Related stories

Ebola Scare In India: 4 People Isolated

Lion cubs die in Gir forest region

Ebola scare in Gujarat